



12th March 2009

ASX RELEASE - ESCROW RELEASE

ImpediMed Limited is required to advise the market 10 working days prior to the release of any shares from escrow. The company wishes to give that advice for a block of 14,370,317 ordinary shares which were originally subject to voluntary escrow until 24th October 2008, and for which a holding lock has remained in place.

The company proposes to release the shares from escrow and remove the holding lock on 30th March 2009.

With respect to the block of shares:

- It constitutes 14,370,317 listed ordinary shares which were originally subject to voluntary escrow until 24th October 2008.
- There are seven holders:
 - 1,212,025 shares Greg Brown
 - A parcel held directly by the CEO and director Greg Brown
 - 97,336 shares Parma Corporation
 - A company associated with the Chairman Mel Bridges
 - 6,395,783 shares Starfish Technology Fund
 - A venture investor in which director Dr Michael Panaccio is a principal
 - 4,832,081 shares Versant Ventures (via 2 investing entities)
 - A US based venture investor
 - 916,546 shares Statewide Superannuation Pty Ltd
 - An institutional investor
 - 916,546 shares Westscheme Pty Ltd
 - An institutional investor

Those holders or controllers who comprise members of the board have confirmed they have no near term plans to dispose of any of the shares on market as a result of their release from escrow. In fact Mr Bridges and Mr Brown have joined other directors in adding to their holdings during the trading window open under the company's share trading policy following release of half year results to 31st December 2008.

The table below summarises ImpediMed's securities on issue following the release from escrow and the ESOP share and option grant advised earlier today.

ImpediMed Limited - Summary of securities on issue								
Instrument	Details	Quoting Status	Escrow Status	Escrowed by Agreement Until	Balance at 30-Jan-2009	ESOP Issue 09-Mar-09	Escrow Release 27-Mar-09	Closing Balance 27-Mar-09
Ord Shares	Shares on Issue Pre-Prospectus	Quoted	Unrestricted	n/a	31,789,017		14,370,317	46,159,334
Ord Shares	Shares on Issue Pre-Prospectus	Quoted	Voluntary Escrow	24/04/2008	-			-
Ord Shares	Shares on Issue Pre-Prospectus	Quoted	Voluntary Escrow	24/10/2008	14,370,317		- 14,370,317	-
Ord Shares	Shares issued through IPO	Quoted	Unrestricted	n/a	25,000,000			25,000,000
Ord Shares	Placement 11th July 2008	Quoted	Unrestricted	n/a	1,600,001			1,600,001
Ord Shares	Placement 30th July 2008	Quoted	Unrestricted	n/a	4,000,000			4,000,000
Ord Shares	Quotation of Xitron Consideration Shares	Quoted	Unrestricted	n/a	2,918,648			2,918,648
Ord Shares	Placement 30th January 2009	Quoted	Unrestricted	n/a	2,857,143			2,857,143
Total Quoted Shares					82,535,126	-	-	82,535,126
Ord Shares	Shares on Issue Pre-Prospectus	Unquoted	Mandatory Escrow	24/10/2009	7,510,126			7,510,126
Ord Shares	Issue on Closing of Xitron Acquisition : 01-Oct-07	Unquoted	Mandatory Escrow	1/10/2008	-			-
Ord Shares	Issue Xitron Acqn Working Cap Adj : 21 Dec 08	Unquoted	Mandatory Escrow	1/10/2008	-			-
Ord Shares	Issue Xitron Acq'n Milestone 1 : 21-Apr-08	Unquoted	Mandatory Escrow	1/10/2008	-			-
Ord Shares	Issue CY2007 Performance Shares - 1/3 vesting	Unquoted	Share Plan Escrow	Conditional	130,749			130,749
Ord Shares	Issue ESOP Share Grant	Unquoted	Share Plan Escrow	Conditional		15,000		15,000
Total Shares on Issue					90,176,001	15,000	-	90,191,001
IPDO Opts	IPO Options issued through Prospectus on IPO	Quoted	Unrestricted	n/a	12,500,000			12,500,000
CEO Opts	Options on issue Pre-Prospectus	Unquoted	Restricted	24/10/2009	747,673			747,673
CEO Opts	Options issued to CEO through Prospectus	Unquoted	Restricted	24/10/2009	1,000,000			1,000,000
ESOP Opts	Options on issue Pre-Prospectus	Unquoted	Unrestricted	n/a	1,590,000			1,590,000
ESOP Opts	Options issued through ESOP - June 2008	Unquoted	Unrestricted	n/a	2,110,000			2,110,000
ESOP Opts	Options issued through ESOP - Mar 2009	Unquoted	Unrestricted	n/a		470,000		470,000
Total Options on Issue					17,947,673	470,000	-	18,417,673

Phil Auckland CFO & Company Secretary

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.